Exhibit 15.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors of Acasti Pharma Inc.

We consent to the incorporation by reference in the registration statements (No. 333-191383) on Form S-8, (No. 333-220755) on Form F-1 and (No. 333-223464) on Form F-3 of Acasti Pharma Inc. of our report dated June 27, 2018, with respect to the statements of financial position as at March 31, 2018 and 2017, the related statements of earnings and comprehensive loss, changes in equity and cash flows for the periods ended March 31, 2018, March 31, 2017 and February 29, 2016, and the related notes (collectively the "financial statements"), which report appears in the annual report on Form 20-F of Acasti Pharma Inc. dated June 29, 2018.

Our report dated June 27, 2018 contains an explanatory paragraph that states that Acasti Pharma Inc. has incurred operating losses and negative cash flows from operations since inception, that its current assets are projected to be significantly less than what will be needed, and that it needs to obtain additional financing, which indicate the existence of a material uncertainty that casts substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that may be necessary if the going concern basis was not appropriate.

Our report dated June 27, 2018 also contains an explanatory paragraph that states that the financial statements of Acasti Pharma Inc. as at February 28, 2017 and for the twelve-month and one-month periods ended February 28, 2017 and March 31, 2017 respectively are unaudited. Accordingly, we do not express an opinion on them.

June 29, 2018

Montréal, Canada

*CPA auditor, CA, public accountancy permit No. A122596

KPMG LLP is a Canadian limited liability partnership and a member firm of the KPMG
network of independent member firms affiliated with KPMG International Cooperative
("KPMG International"), a Swiss entity.
KPMG Canada provides services to KPMG LLP.